Claims for Patent: 10,143,652

Summary for Patent: 10,143,652

Title:	Methods for the preparation of liposomes
Abstract:	Provided herein are methods for preparing liposomes and uses thereof. In certain embodiments, liposomes are prepared without using heat, organic solvents, proteins, and/or inorganic salts in the process. In certain embodiments, the liposomal preparation contains one or more active agents. In certain embodiments, the liposomal preparations are used in the treatment of diseases or disorders.
Inventor(s):	Javeri; Indu (North Andover, MA), Nellaiappan; Kaliappanadar (Lexington, MA)
Assignee:	CuriRx Inc. (Wilmington, MA)
Application Number:	15/226,364
Patent Claims:	1. A liposome-associated antibody composition, comprising a plurality of antibody molecules non-covalently associated with a hydrophobic membrane region of a plurality of unilamellar liposomes via non-covalent binding directly between the antibody molecules and lipid molecules in the hydrophobic membrane region not mediated by chemical modification of the antibody molecules or lipid molecules, wherein the liposome-associated antibody is stabilized against aggregation. 2. The liposome-associated antibody composition of claim 1 which is devoid of covalently conjugated antibody molecules. 3. The liposome-associated antibody composition of claim 1, wherein the molar ratio of liposomal lipid to antibody is about 50 or less. 4. The liposome-associated antibody composition of claim 1, wherein the plurality of liposomes are suspended in an aqueous medium. 5. The liposome-associated antibody composition of claim 4, wherein the total concentration of antibody in the aqueous medium is at least about 5 mg/mL. 6. The liposome-associated antibody composition of claim 1 which is lyophilized. 7. The liposome-associated antibody composition of claim 1, wherein the plurality of liposomes comprise soybean phosphatidylcholine. 8. The liposome-associated antibody composition of claim 1, wherein the composition comprises trehalose. 9. The liposome-associated antibody composition of claim 1 which is essentially devoid of antibody molecules that are not bound to a hydrophobic membrane region of the plurality of liposomes. 10. The liposome-associated antibody composition of claim 1, wherein the antibody is trastuzumab or adalimumab. 11. A method of preparing a liposome-associated antibody composition, the method comprising the steps of: (a) providing a lyophilized or solubilized antibody and an aqueous suspension of unilamellar liposomes; (b) contacting the antibody with the aqueous suspension of liposomes, whereby the antibody becomes associated with a hydrophobic membrane region of the liposomes via non-covalent binding directly between the antibody molecules and lipid molecules in the hydrophobic membrane region not mediated by chemical modification of the antibody molecules or lipid molecules; wherein the liposome-associated antibody is stabilized against aggregation. 12. The method of claim 11, further comprising: (c) separating liposome-associated antibody from antibody not associated with liposomes. 13. The method of claim 12, further comprising: (d) lyophilizing the liposome-associated antibody composition. 14. The method of claim 11 wherein step (b) is performed without the further use of homogenization, shear, microfluidization, or filtration after adding the antibody. 15. The method of claim 11, wherein at least 60% of the antibody becomes associated with the liposomes. 16. The method of claim 11, wherein the liposomes comprise soybean phosphatidylcholine and the antibody is trastuzumab or adalimumab. 17. The method of claim 11, wherein the antibody is not exposed to a detergent or an organic solvent, and wherein the antibody is not loaded into the liposomes with the use of an osmotic or pH gradient, or with the use of freeze-thaw of the aqueous suspension of liposomes.

Details for Patent 10,143,652

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2029-09-23
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2029-09-23
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002		2029-09-23
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008		2029-09-23